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Published online: 27 November 2013 # Springer-Verlag Berlin Heidelberg 2013 "It is too violent to gather up the four movements of such different characters under the name of Sonata! But this piece is incredibly beautiful…" This historic quote was made by Robert Schumann in reference to the second piano sonata by Frederic Chopin that contains the famous funeral march. When experiencing the sonata for the first time, one may feel that this piece is somewhat "slippery", as the association between the movements appears obscure due to the musical independency and distinctive color of each movement. However, after having heard the whole piece, one will no longer find any cracks in the artistic structure and will be fully convinced that the four movements form a definite complex. In fact, this is brought about by the common motif with a minor third, which is used throughout the sonata in the form of various metaphors; thus, it is not obvious at first glance. This motif links all the movements, thereby providing unity to the masterpiece.
The prominent increase in the incidence of obesity in modern society has been caused by rapid and extreme changes in lifestyle, particularly eating habits. Obesity induces multiple diseases, each of which threatens our health and is a burden on medical expenses. Examples includes type 2 diabetes, atherosclerosis followed by cardiovascular complications, fatty liver diseases giving rise to liver fibrosis and cancer, and, interestingly, autoimmune diseases. At a glance, these diseases appear independent of each other: the pathogenesis of each disease is distinctive, the major affected organ in each disease is different, and each disease is treated and studied by its own specialists. However, all these diseases are manifestations of metabolic syndrome, which is the most talked about disease complex in modern society. In this sense, the relationship between metabolic syndrome and its associated diseases is reminiscent of the second sonata by Chopin and its four movements. Then, what is the minor third motif that mechanistically links all these different diseases? Accumulating evidence indicates that the answer to this question is inflammation.
The breakthrough in understanding the events which bridge obesity and its associated diseases was brought about by the discovery that the chronic, low-grade inflammation observed in obese adipose tissue is responsible for triggering insulin resistance. In recent years, it has become clear that infiltration of a large number of classically activated inflammatory macrophages (M1 macrophages) into adipose tissue is responsible for obesity-associated inflammation. Lean adipose tissue contains a resident population of alternatively activated macrophages (M2 macrophages), which can suppress inflammation in both adipocytes and macrophages themselves, partly via secreting interleukin 10. Hence, obesity induces a switch in the macrophage activation state in adipose tissue toward M1 polarization, which induces inflammation. Such subclinical inflammation of adipose tissue is closely associated with insulin resistance not only in adipose tissue, but also systemically, thus contributing to the development of multiple obesity-induced metabolic and cardiovascular diseases.
In this issue, the authors introduce eight variations of obesity-associated disease linked by the motif of inflammation. Arai et al. discuss adipose tissue macrophage recruitment with a focus on the newly identified role of apoptosis inhibitor of macrophage (AIM), a macrophage-derived blood protein initially identified as an apoptosis inhibitor that supports macrophage survival. Under obese conditions, augmented blood AIM is incorporated into adipocytes via CD36-mediated endocytosis and induces vigorous lipolysis. The authors show how this AIM-induced lipolytic response influences the recruitment of inflammatory macrophages and subsequent insulin resistance. In addition to the accumulation of information on the immune responses within adipose tissue triggered by macrophages, recent studies have also highlighted the impact of other metabolic organs such as the liver and skeletal muscles in view of the pathological immune responses that cause metabolic disorders. Eheim et al. precisely present recent progress in this area of metabolic research, while Eisele et al. pay special attention to the pathophysiological state in skeletal muscle. Specifically, Eisele et al. highlight the roles of peroxisome proliferator-activated receptor γ coactivator 1 (PGC-1) as an important mediator of oxidative metabolism and discuss the functional crosstalk between PGC-1 and inflammation in the nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) pathway. On the other hand, Najjar describes both currently known and proposed pathogenic aspects of non-alcoholic steatohepatitis (NASH), a hepatic manifestation of metabolic syndrome, within the context of inflammatory regulation. In recent years, increased attention has been paid to NASH, particularly due to the rapid decrease in the number of new patients with hepatitis viral infection or severe alcoholic liver injury. Although it is widely known that NASH progresses to cirrhosis and hepatocellular carcinoma, its precise pathogenesis remains unclear and no effective therapeutic strategy has been developed. Najjar also proposes an important role for carcinoembryonic antigenrelated cell adhesion molecule 1 as a link between immunological and metabolic abnormalities in the pathology of NASH. In contrast to these discussions on inflammatory state mainly in response to activation of the innate immune system, Garrido-Urbani et al. and Subramanian et al. focus more on the involvement of adoptive immunity in the pathogenesis of atherosclerosis. In particular, Subramanian et al. look at the role of dendritic cells (DCs) in the pathogenesis of atherosclerosis and discuss the possibility of DC-based therapeutic strategies. Furthermore, Arai et al. describe the relationship between obesity and autoantibody production, again in the context of AIM.
In addition to these important findings, one of the recent high-impact topics in the metabolic research field is the important role that gut microbiota play in the regulation of physiological and pathological states in multiple metabolic organs. This rapidly growing research field emerged following the groundbreaking results reported by Gordon's group, namely that the repertoire of gut microbiota in mice was altered with obesity progression and that a transfer of microbiota from obese mice to lean mice induced obesity. Here, two articles cover the recent progress in this field. Fukuda et al. provide a grand overview of the influence of gut microbiota on obesity and its associated inflammatory diseases. Imajo et al. propose microbiota manipulation as a therapeutic strategy for obesity, diabetes, and NASH. In particular, they present the strong involvement of gut microbiota in NASH progression, which is achieved through multiple pathways including activation of innate immunity.
Hopefully, readers will now see that metabolic syndrome is in its own way like a sonata, with selfsufficient movements united through an essential common motif. In other words, each associated disease shares a common key mechanism. Accordingly, mutual suppression of a specific disease might even positively influence the progression of other diseases. Hence, targeting inflammation to tune the harmony of different physiologies in multiple metabolic organs might be a promising nextgeneration therapy for metabolic syndrome. To this end, we should consider taking to the conductor's podium to oversee the orchestral collection of the many metabolic diseases. The editor thanks the authors for their precious contributions and hopes that readers will savor the timely topics presented in this issue.
